Search Results

A Phase 1b Clinical Study of NXP900 in Combination with Osimertinib in Subjects with Advanced, EGFRMut+ Non-Small Cell Lung Cancer (NXP900-103) MOA: NXP900 is an orally bioavailable small molecular and potent inhibitor of kinases from the SRC family of kinases (SFK). Key Eligibility: Unresectable, met/LA EGFRMut+ NSCLC Plasma or tissue may be used for ctDNA,…

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib plus Pembrolizumab plus Chemotherapy vs. Placebo plus Pembrolizumab plus Chemotherapy in Participants with Previously Untreated, Locally Advanced or Metastatic Non-squamous Non small Cell Lung Cancer with KRAS G12C Mutation (KRYSTAL-4) MOA: Adagrasib is an oral, selective inhibitor of KRASG12C mutant Key Eligibility: Histologically or cytologically confirmed diagnosis…

A Study to Evaluate the Safety and Tolerability of the Covalent Phosphoinositide-3-Kinase (PI3K) alpha Inhibitor, TOS-358, in Adult Subjects with Select Solid Tumors MOA: TOS-358 is a covalent inhibitor of WT and mutant PI3Kα and has much better toxicity profile compared to other inhibitors in this class Key Eligibility: HR+/HER2- LA/rec or MBC with PIK3CA…

One in eight men will develop prostate cancer in their lifetimes, but thanks to an increase in screening, most prostate cancers will be diagnosed early while the tumor is still small and has not spread. At this stage, prostate cancer is highly treatable, and patients may weigh their options as they consider different treatments. How…

You are attuned to your partner’s moods, habits, and appearance, so it is easy to spot when your other half looks pale, seems tired or is acting differently. Because of closeness and intimacy, you may also detect lumps or other physical changes your mate may not have noticed. This familiarity can help you flag health…